Adaptive Biotechnologies：微量殘留病灶業務拆分打造純粹的複利成長公司 (NASDAQ:ADPT)
· seekingalpha.com
Adaptive Biotechnologies (ADPT) 轉向成為純粹的微量殘留病灶 (MRD) 診斷公司，受益於 clonoSEQ 採用率、利潤率及積壓訂單的激增。
My current bullish outlook on Adaptive Biotechnologies Corporation ( ADPT ) stems from the economic and financial change in the business rather than the science...